Oncogenic osteomalacia: loss of hypophosphatemia might be the key to avoid misdiagnosis

• Autor(a) principal: Chang, Cláudia
• Data de Publicação: 2012
• Outros Autores: Conde, Sandro José [UNESP], Luvizotto, Renata A. M. [UNESP], Nunes, Vânia S. [UNESP], Bonates, Milla C. [UNESP], Felicio, Andre C., Lindsey, Susan C. [UNESP], Moraes, Flávia H. [UNESP], Tagliarini, José V. [UNESP], Mazeto, Glaucia M. F. [UNESP], Kopp, Peter, Nogueira, Célia R. [UNESP]
• Tipo de documento: Conjunto de dados
• Idioma: eng
• Título da fonte: Repositório Institucional da UNESP (dados de pesquisa)
• Texto Completo: http://www.scielo.br/scielo.php?script=sci_abstract&pid=S0004-27302012000800018&lng=en&nrm=iso&tlng=en; http://hdl.handle.net/11449/137688

Diagnosing oncogenic osteomalacia is still a challenge. The disorder is characterized by osteomalacia caused by renal phosphate wasting and low serum concentration of 1,25-dihydroxyvitamin D3 occurring in the presence of a tumor that produces high levels of fibroblast growth factor 23. However, it is possible that the disease is much more misdiagnosed than rare. We present the case of a 42-year-old man with a long-term history of undiagnosed progressive muscle weakness. His laboratory results mainly showed low serum phosphate. Surgical removal of a nasal hemangiopericytoma that had been diagnosed five years earlier, brought him to a symptom-free condition. Even though knowing the underlying etiology would explain his osteomalacia, the patient sought medical help from countless physicians for five consecutive years, and only after adequate treatment a rewarding outcome was achieved.